Usability of the CollaGUARD Adhesion Barrier Following Hysteroscopic Adhesiolysis
Launched by INNOCOLL · Jan 27, 2015
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Intrauterine adhesions following gynaecological surgery is a major complication which may cause a range of severe clinical symptoms in women. IUA's can result in menstrual abnormalities, dysmenorrhea and infertility. In pregnancy, adhesions are related to miscarriage, ectopic pregnancy, abnormal placentation, premature labor and delivery and possibly birth defects.
CollaGUARD adhesion barrier is a transparent bioresorbable film approved in Europe for the prevention of postoperative adhesions in patients undergoing abdomino-pelvic laparotomy or laparoscopy.
This study will assess the feasi...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with intrauterine adhesions and found eligible for hysteroscopic adhesiolysis
- • Willing to use additional contraception throughout study
- Exclusion Criteria:
- • Be pregnant or having a suspected molar pregnancy, lactating, or planning to become pregnant at any time during the study
- • Has suffered or currently suffers from a gynaecological malignancy
- • Has undergone a previous hysteroscopic surgery (such as removal of fibroids)
About Innocoll
Innocoll is a leading biotechnology company focused on developing and commercializing innovative therapeutic solutions for unmet medical needs, particularly in the fields of wound care and surgical medicine. With a commitment to advancing patient outcomes, Innocoll leverages its proprietary delivery technologies to create products that enhance the efficacy and safety of existing therapies. The company prioritizes rigorous clinical research and collaboration with healthcare professionals to ensure that its products meet the highest standards of quality and effectiveness. Innocoll is dedicated to improving the lives of patients through groundbreaking solutions that address critical challenges in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hoofddorp, , Netherlands
Amsterdam, , Netherlands
Patients applied
Trial Officials
David Prior, PhD
Study Director
Sponsor GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials